Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Onkure Therapeutics Inc OKUR

Healthcare Biotechnology
OnKure Therapeutics, Inc., formerly Reneo Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a robust pipeline of tumor-agnostic candidates. The... see more

Recent & Breaking News (NDAQ:OKUR)

OnKure Announces New Date for Upcoming Investor Call

GlobeNewswire 6 hours ago

OnKure to Present at the Stifel 2024 Healthcare Conference

GlobeNewswire November 5, 2024

OnKure to Present Clinical and Preclinical Data for OKI-219 at the 2024 San Antonio Breast Cancer Symposium

GlobeNewswire November 1, 2024

OnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 Million

GlobeNewswire October 4, 2024

Reneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKure

GlobeNewswire October 2, 2024

RPHM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Reneo Pharmaceuticals, Inc. Is Fair to Shareholders

Business Wire September 3, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VAPO, SGE, RPHM, SQSP on Behalf of Shareholders

PR Newswire August 29, 2024

RENEO PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM

Business Wire August 29, 2024

Reneo Pharmaceuticals Reports Second Quarter 2024 Financial Results

GlobeNewswire August 13, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RPHM, VAPO, PRFT on Behalf of Shareholders

PR Newswire July 1, 2024

Kuehn Law Encourages INFN, RPHM, VAPO, and PRFT Investors to Contact Law Firm

PR Newswire July 1, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SQSP, RPHM, VAPO on Behalf of Shareholders

Accesswire June 26, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALE, RPHM, SQSP on Behalf of Shareholders

PR Newswire June 24, 2024

STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHM

PR Newswire June 24, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Continues to Investigate PRFT, SBOW, RPHM, AGR

PR Newswire May 30, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RPHM, WIRE, BCAL, AIRC

PR Newswire May 23, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SBOW, PRFT, RPHM

PR Newswire May 20, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALE, RPHM, AGS

PR Newswire May 16, 2024

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RPHM, ALE, HRT

Accesswire May 15, 2024

SHAREHOLDER ALERT: Halper Sadeh LLC Continues to Investigate SQSP, RPHM, ALE, HRT

Accesswire May 14, 2024